CNCao Hoang Long Ngo

Cao Hoang Long Ngo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cao Hoang Long Ngo has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Proteomics Study of Breast Cancer-Derived Small Extracellular Vesicles: Unveiling Potential Cancer Biomarkers

    by Cao Hoang Long Ngo, Su Su Thae Hnit, Wei Zhang, Xin Feng, Victoria Ie Ching Tan, Lianghai Hu, Simon Chang-Hao Tsao, Yuling Wang

    Small extracellular vesicles (sEVs) are lipid-bilayer-enclosed vesicles secreted by cells into the extracellular environment, carrying a variety of biomolecules, including proteins that reflect the molecular profile of their cell of origin. In particular, cancer-derived sEVs hold significant potential for cancer diagnosis due to their unique biomolecular content. In this study, we utilized mass spectrometry to profile the protein expression in plasma-derived sEVs from both healthy controls (HCs) and breast cancer (BC) patients with the aim of discovering new protein biomarkers for potential BC diagnosis. Through the cross-validation of differentially expressed proteins between the two independent cohorts, we identified nine proteins that were significantly upregulated in BC-derived sEVs. Further validation using online gene expression data sets, Western blot, and ELISA revealed that OIT3 was upregulated in BC tissue compared to HC tissue, suggesting its potential as a novel BC biomarker. These findings contribute to advancing the knowledge of proteins within sEVs, as well as offering promising avenues for the use of sEVs as biomarkers in future cancer diagnostic applications.


  • On-Chip Profiling of Bacterially Infected Host Cell-Derived Small Extracellular Vesicles by Surface-Enhanced Raman Scattering

    by Nana Lyu, Amin Hassanzadeh-Barforoushi, Wei Zhang, Cao Hoang Long Ngo, Su Su Thae Hnit, David W. Inglis, Yuling Wang

    Small extracellular vesicles (sEVs) are membrane-bound nanoparticles (Pseudomonas aeruginosa strain PAO1. This platform integrates host-pathogen coculture with on-chip sEV capture and multiplexed molecular profiling of host cell-derived sEVs. A two-layer modular design enables stepwise cell loading, controlled coculture, and efficient sEV capture through hydrophobic interactions between the sEV membrane and silane-modified polymer that modified on the chip. Multiplexed surface-enhanced Raman scattering (SERS) nanotags allow simultaneous detection of key sEV biomarkers from A549 cells (CD81, EGFR, EpCAM), and PAO1 (oprF). Through SERS mapping, molecular signatures across sEVs are spatially resolved, providing insights into compositional changes in sEVs following PAO1 exposure. By minimizing direct bacterial contact and relying on diffusion-driven capture, the system more closely mimics physiological infection processes.


  • A New Strategy to Modify Glass for Capture and Detection of Small Extracellular Vesicles

    by Cao Hoang Long Ngo, Su Su Thae Hnit, Amin Hassanzadeh-Barforoushi, Faiza Chowdhury, Wei Zhang, David W. Inglis, Simon Chang-Hao Tsao, Yuling Wang

    Small extracellular vesicles (sEVs) are nanoscale lipid bilayer vesicles secreted from all types of cells to the extracellular environment. They inherit membrane proteins from their parent cells, making them one of the key biomaterials or biomarkers for disease diagnosis. Microfluidics is emerging as a promising platform for sEV capture, with many methods relying on the modification to a glass substrate for efficient capture. In this study, we propose a new, one-step surface modification method, using silane─poly(ethylene glycol) (PEG) - 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), named as silane-PEG-DSPE, to capture sEVs on glass. In this design, silane group attaches to hydroxylated glass surface via covalent bond between Si-(OEt)3 and hydroxyl (OH) group. DSPE then binds to sEVs with distearyl chains firmly anchoring to the vesicle lipid membrane. We determined the optimal conditions for silane-PEG-DSPE modification and tested the efficiency of silane-PEG-DSPE in capturing sEVs by fluorescent imaging. Additionally, surface-enhanced Raman scattering (SERS) demonstrated that the EpCAM-positive sEVs were presented on the glass surface. This suggests that the platform is applicable for sEV detection using various methods, including fluorescent imaging and SERS. Furthermore, we have demonstrated that SERS can detect sEVs from breast cancer (BC) patient plasma with high specificity and sensitivity (as low as 1.6 × 107 particles/mL). Additionally, our analysis reveals a significantly higher expression of EpCAM in BC-derived sEVs compared with those obtained from healthy individuals. Thus, we postulate that the proposed method will find broad applications in the future, particularly as an effective tool in cancer diagnosis.


  • Open Access

    Recent Advances in Cancer Cell Membrane‐Based Nanoparticles and Cancer Cell‐Derived Small Extracellular Vesicles as Drug Delivery Platforms

    by Wei Zhang, Jingjing Wang, Long Ngo, Li Li, Yuling Wang

    Advances in nanotechnology have paved the way for innovative drug delivery systems that enhance the effectiveness of cancer treatment. Cancer cell membrane‐based nanoparticles (CCM‐NPs) and cancer cell‐derived small extracellular vesicles (CsEVs) are emerging as promising drug delivery systems for cancer treatment due to their inherent properties such as low immunogenicity and natural targeting capabilities to cancer cells. However, a comprehensive comparison of the advantages, disadvantages, and similarities of these two platforms is lacking. This review summarizes the natural, engineered, and hybrid forms of CCM‐NPs and CsEVs‐based drug delivery platforms with a focus on comparison of these two platforms, considering key aspects including preparation methods, drug encapsulation strategies, delivery pathways, immune evasion, targeting ability, and their potential for clinical applications. By understanding the strengths and weaknesses of each approach, the aim is to pave the way for next‐generation nanoscale drug delivery platforms and contribute to the development of more effective and personalized cancer therapies.


  • Sensitive detection of small extracellular vesicles using a gold nanostar-based SERS assay

    by Cao Hoang Long Ngo, Anastasiia Tukova, Wei Zhang, Simon Chang-Hao Tsao, Yuling Wang

    Small extracellular vesicles (sEVs) are lipid bilayer-bound vesicles that carry critical biomarkers for disease detection. However, the inherent heterogeneity and complexity of sEV molecular characteristics pose significant challenges for accurate and comprehensive molecular profiling. Traditional analytical methods, including immunoblotting, enzyme-linked immunosorbent assay (ELISA), and flow cytometry, exhibit several limitations, such as being time-consuming, requiring large sample volumes, and demonstrating relatively low sensitivity. Therefore, there is an urgent need to develop a highly sensitive and specific assay for the reliable detection of sEVs. Surface-enhanced Raman scattering (SERS) assays have emerged as a promising approach for sEV detection, offering advantages including high sensitivity and specificity. In the proposed SERS assay, SERS nanotags – comprising nanoparticles coated with Raman-active molecules and conjugated with antibodies – are employed to label surface-bound molecules on sEVs. This approach facilitates the generation of a high-intensity signal from molecules present in low abundance. Recently, anisotropic nanoparticles, such as star-shaped nanostructures, have garnered interest due to their ability to significantly amplify generated SERS signals for ultra-sensitive biomarker detection. In this study, we explore the application of gold nanostars (AuNSs) as SERS nanotags for the detection of sEVs. In principle, AuNS-based SERS nanotags were used to label the EpCAM protein, which can be found on the surface of cancer cell derived sEVs, and then sEV labelled SERS nanotags were captured by CD9-conjugated magnetic beads to form an immunocomplex, which exhibits a SERS signal. Our results demonstrate that the proposed SERS assay utilizing AuNSs provides high specificity and sensitivity, with a detection limit as low as 2.47 × 103 particles per μL. Furthermore, the assay was tested with spiked plasma samples (cancer cell-derived sEVs spiked into healthy plasma), showing that its specificity remains unaffected by the presence of plasma. These findings suggest that the SERS assay incorporating AuNSs holds significant promise as an effective and reliable detection method for potential clinical applications.


  • Improving SERS biosensors for the analysis of ovarian cancer-derived small extracellular vesicles

    by Long Ngo, Wei Zhang, Su Su Thae Hnit, Yuling Wang

    An improved SERS assay was reported to detect ovarian cancer derived-small extracellular vesicles (sEVs) down to 1.5 × 10 5 particles per μL. The surface protein biomarkers on sEVs were profiled, showing high sensitivity and specificity of the SERS assay.


  • Emerging integrated SERS-microfluidic devices for analysis of cancer-derived small extracellular vesicles

    by Long Ngo, Le Que Anh Pham, Anastasiia Tukova, Amin Hassanzadeh-Barforoushi, Wei Zhang, Yuling Wang

    Cancer-derived small extracellular vesicles (sEVs) are specific subgroups of lipid bilayer vesicles secreted from cancer cells to the extracellular environment. They carry distinct biomolecules (e.g., proteins, lipids and nucleic acids) from their parent cancer cells. Therefore, the analysis of cancer-derived sEVs can provide valuable information for cancer diagnosis. However, the use of cancer-derived sEVs in clinics is still limited due to their small size, low amounts in circulating fluids, and heterogeneous molecular features, making their isolation and analysis challenging. Recently, microfluidic technology has gained great attention for its ability to isolate sEVs in minimal volume. In addition, microfluidics allows the isolation and detection of sEVs to be integrated into a single device, offering new opportunities for clinical application. Among various detection techniques, surface-enhanced Raman scattering (SERS) has emerged as a promising candidate for integrating with microfluidic devices due to its ultra-sensitivity, stability, rapid readout, and multiplexing capability. In this tutorial review, we start with the design of microfluidics devices for isolation of sEVs and introduce the key factors to be considered for the design, and then discuss the integration of SERS and microfluidic devices by providing descriptive examples of the currently developed platforms. Lastly, we discuss the current limitations and provide our insights for utilising integrated SERS-microfluidics to isolate and analyse cancer-derived sEVs in clinical settings.